Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 19, 2007
- MEDICAL DEVICE NEWS IN BRIEF
March 19, 2007
- 7 APIs Including Celecoxib to Be Included in NHI Price List
March 19, 2007
- Efficacy of Narcotic Analgesics Predicted by Gene Polymorphisms
March 19, 2007
- Gov't-Private Sector Dialogueto Be Held on Distribution
March 19, 2007
- Consider Licensing, Not Independent Marketing, in Advanced Countries: Mr Seko
March 19, 2007
- Warning against Exacerbation of Hepatitis Added to Package Insert of Rituximab
March 19, 2007
- Amended PAL Presents Opportunities: JACDS
March 19, 2007
- REGULATORY NEWS IN BRIEF
March 19, 2007
- 6-Year Education Makes Schools of Pharmacy Less Attractive: Survey
March 19, 2007
- PMDA to Hire 236 New Reviewers by End of FY2009
March 19, 2007
- Global Sales of 3 New Strategic Products to Exceed US$1.5 Bil. Each: Mr Naito
March 19, 2007
- Lactoferrin Improves Dyslipidemia: Lion
March 19, 2007
- Seretide Reduces Risk of Death in COPD: GSK
March 19, 2007
- Japan, China Agree to Cooperate in Developing Anticancer Drugs
March 19, 2007
- SymBio Completes Enrollment into PI Trial of Bendamustine
March 19, 2007
- Preminent Maintains Top Position: Rep Track Survey
March 12, 2007
- Pfizer Japan Needs Flat, Agile Organization: Mr Iwasaki
March 12, 2007
- DSM to Expand Its Business in Life Sciences
March 12, 2007
- BUSINESS NEWS IN BRIEF
March 12, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…